These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

349 related articles for article (PubMed ID: 7888224)

  • 1. A broadly neutralizing human monoclonal antibody against gp41 of human immunodeficiency virus type 1.
    Purtscher M; Trkola A; Gruber G; Buchacher A; Predl R; Steindl F; Tauer C; Berger R; Barrett N; Jungbauer A
    AIDS Res Hum Retroviruses; 1994 Dec; 10(12):1651-8. PubMed ID: 7888224
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multifaceted consequences of anti-gp41 monoclonal antibody 2F5 binding to HIV type 1 virions.
    Neurath AR; Strick N; Lin K; Jiang S
    AIDS Res Hum Retroviruses; 1995 Jun; 11(6):687-96. PubMed ID: 7576928
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HIV-1 vaccine development: constrained peptide immunogens show improved binding to the anti-HIV-1 gp41 MAb.
    McGaughey GB; Citron M; Danzeisen RC; Freidinger RM; Garsky VM; Hurni WM; Joyce JG; Liang X; Miller M; Shiver J; Bogusky MJ
    Biochemistry; 2003 Mar; 42(11):3214-23. PubMed ID: 12641452
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1.
    Muster T; Steindl F; Purtscher M; Trkola A; Klima A; Himmler G; Rüker F; Katinger H
    J Virol; 1993 Nov; 67(11):6642-7. PubMed ID: 7692082
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A human monoclonal antibody to HIV-1 gp41 with neutralizing activity against diverse laboratory isolates.
    Cotropia J; Ugen KE; Kliks S; Broliden K; Broliden PA; Hoxie JA; Srikantan V; Williams WV; Weiner DB
    J Acquir Immune Defic Syndr Hum Retrovirol; 1996 Jul; 12(3):221-32. PubMed ID: 8673526
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A potent cross-clade neutralizing human monoclonal antibody against a novel epitope on gp41 of human immunodeficiency virus type 1.
    Stiegler G; Kunert R; Purtscher M; Wolbank S; Voglauer R; Steindl F; Katinger H
    AIDS Res Hum Retroviruses; 2001 Dec; 17(18):1757-65. PubMed ID: 11788027
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An affinity-enhanced neutralizing antibody against the membrane-proximal external region of human immunodeficiency virus type 1 gp41 recognizes an epitope between those of 2F5 and 4E10.
    Nelson JD; Brunel FM; Jensen R; Crooks ET; Cardoso RM; Wang M; Hessell A; Wilson IA; Binley JM; Dawson PE; Burton DR; Zwick MB
    J Virol; 2007 Apr; 81(8):4033-43. PubMed ID: 17287272
    [TBL] [Abstract][Full Text] [Related]  

  • 8. N-terminal residues of an HIV-1 gp41 membrane-proximal external region antigen influence broadly neutralizing 2F5-like antibodies.
    Li D; Liu J; Zhang L; Xu T; Chen J; Wang L; Zhao Q
    Virol Sin; 2015 Dec; 30(6):449-56. PubMed ID: 26715302
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neutralization of divergent human immunodeficiency virus type 1 variants and primary isolates by IAM-41-2F5, an anti-gp41 human monoclonal antibody.
    Conley AJ; Kessler JA; Boots LJ; Tung JS; Arnold BA; Keller PM; Shaw AR; Emini EA
    Proc Natl Acad Sci U S A; 1994 Apr; 91(8):3348-52. PubMed ID: 7512731
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunogenic presentation of a conserved gp41 epitope of human immunodeficiency virus type 1 on recombinant surface antigen of hepatitis B virus.
    Eckhart L; Raffelsberger W; Ferko B; Klima A; Purtscher M; Katinger H; Rüker F
    J Gen Virol; 1996 Sep; 77 ( Pt 9)():2001-8. PubMed ID: 8810996
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The broadly neutralizing anti-human immunodeficiency virus type 1 4E10 monoclonal antibody is better adapted to membrane-bound epitope recognition and blocking than 2F5.
    Huarte N; Lorizate M; Maeso R; Kunert R; Arranz R; Valpuesta JM; Nieva JL
    J Virol; 2008 Sep; 82(18):8986-96. PubMed ID: 18596094
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of a novel human immunodeficiency virus type 1 neutralizable epitope within the immunodominant region of gp41.
    Viveros M; Dickey C; Cotropia JP; Gevorkian G; Larralde C; Broliden K; Levi M; Burgess A; Cao C; Weiner DB; Agadjanyan MG; Ugen KE
    Virology; 2000 Apr; 270(1):135-45. PubMed ID: 10772986
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Crystal structure of the complex between the F(ab)' fragment of the cross-neutralizing anti-HIV-1 antibody 2F5 and the F(ab) fragment of its anti-idiotypic antibody 3H6.
    Bryson S; Julien JP; Isenman DE; Kunert R; Katinger H; Pai EF
    J Mol Biol; 2008 Oct; 382(4):910-9. PubMed ID: 18692506
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fine definition of the epitope on the gp41 glycoprotein of human immunodeficiency virus type 1 for the neutralizing monoclonal antibody 2F5.
    Parker CE; Deterding LJ; Hager-Braun C; Binley JM; Schülke N; Katinger H; Moore JP; Tomer KB
    J Virol; 2001 Nov; 75(22):10906-11. PubMed ID: 11602730
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunogenic and antigenic dominance of a nonneutralizing epitope over a highly conserved neutralizing epitope in the gp41 envelope glycoprotein of human immunodeficiency virus type 1: its deletion leads to a strong neutralizing response.
    Cleveland SM; Buratti E; Jones TD; North P; Baralle F; McLain L; McInerney T; Durrani Z; Dimmock NJ
    Virology; 2000 Jan; 266(1):66-78. PubMed ID: 10612661
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lipid modulation of membrane-bound epitope recognition and blocking by HIV-1 neutralizing antibodies.
    Huarte N; Lorizate M; Kunert R; Nieva JL
    FEBS Lett; 2008 Nov; 582(27):3798-804. PubMed ID: 18930052
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41.
    Zwick MB; Labrijn AF; Wang M; Spenlehauer C; Saphire EO; Binley JM; Moore JP; Stiegler G; Katinger H; Burton DR; Parren PW
    J Virol; 2001 Nov; 75(22):10892-905. PubMed ID: 11602729
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Progress towards the development of a HIV-1 gp41-directed vaccine.
    McGaughey GB; Barbato G; Bianchi E; Freidinger RM; Garsky VM; Hurni WM; Joyce JG; Liang X; Miller MD; Pessi A; Shiver JW; Bogusky MJ
    Curr HIV Res; 2004 Apr; 2(2):193-204. PubMed ID: 15078183
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Construction of peptide mimetics of an epitope of the human immunodeficiency virus (HIV-1) gp41 protein, recognized by virus-neutralizing antibodies 2F5].
    Tumanova OIu; Kuvshinov VN; Azaev MSh; Masharskiĭ AE; Klimov NA; Kozlov AP; Il'ichev AA; Sandakhchiev LS
    Mol Biol (Mosk); 2001; 35(1):146-51. PubMed ID: 11234374
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human immunodeficiency virus type 1-neutralizing monoclonal antibody 2F5 is multispecific for sequences flanking the DKW core epitope.
    Menendez A; Chow KC; Pan OC; Scott JK
    J Mol Biol; 2004 Apr; 338(2):311-27. PubMed ID: 15066434
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.